Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?

Eli Lilly's stock has soared due to strong sales of its diabetes and weight management drug, tirzepatide, leading to a raised revenue outlook for 2024. Analysts remain optimistic, with a potential 17% increase in stock price over the next year. However, despite the drug's edge over competitors like Novo Nordisk's semaglutide, Eli Lilly's high valuation raises concerns about sustainability and risk for investors. Wall Street's high expectations could pose risks if growth slows, suggesting caution for those with lower risk tolerance.